Few important advances in the treatment of acute pain have
been made over the past few decades, so this market is one of numerous low-cost
generics competing against a small number of reformulated brands that
incorporate conventional analgesics (e.g., opioid analgesics, NSAIDs, local
anesthetics) into more-patient-friendly products. Nevertheless, there are niche
opportunities for drug developers who can address key areas of unmet need, the
most important of which are for potent, opioid-sparing analgesics for
postoperative pain and effective analgesics for opioid-refractory severe pain.
The sheer size of the acute musculoskeletal pain patient segment also presents
opportunity for developers who can offer safe and effective alternatives to
oral NSAIDs (the current gold standard for this kind of pain).
Questions Answered in This Report:
Growing use of
opioid-sparing analgesics in the postoperative environment will reduce the need
for strong opioids in this setting. How will this trend affect overall
opioid analgesic sales for acute pain? In which markets will new opioid-sparing
analgesics have the greatest impact?
Locally acting transdermal
NSAIDs will offer oral NSAID-strength pain relief but with minimal systemic
exposure for patients with highly localized pain. How will these new
prescription-strength NSAIDs be received by physicians and patients once they
reach the market? How will third-party payer reimbursement of these
comparatively expensive new NSAIDs affect their uptake?
specialists look forward to the introduction of long-acting bupivacaine
products for postoperative pain. How will these expensive new products fare
once they reach the market? Will lingering concerns about potential toxicity
limit these new agents’ uptake in the hospital sector?
Risk Evaluation and Mitigation Strategies (REMS) are being applied to many
strong opioids in the United States. How will these restrictions affect drug
treatment of acute pain? Which current and emerging agents will be most
affected? Which patient sectors will be most affected?
Most triptans will lose
patent protection between 2012 and 2015. How will genericization affect
uptake of expensive new migraine-specific agents like Merck’s telcagepant? Will
the genericization of the triptan market boost PCP/GP prescribing of these
agents for migraine?
Markets covered: United States, France, Germany,
Italy, Spain, United Kingdom, Japan.
Primary research: 63 country-specific interviews with pain
specialists and researchers.
Epidemiology: Prevalent cases of breakthrough cancer pain,
prevalent cases of migraine and number of migraine attacks, number of incident
events of select surgical procedures, prevalent cases of acute musculoskeletal
pain (by number of involved sites), prevalent cases of acute low back pain,
prevalent cases of acute neck pain.
Emerging therapies: Phase II: 6 drugs; Phase III: 18 drugs;
preregistration: 4 drugs.
features: We segment key acute
pain populations in the base year (2008), segment the base-year market by
hospital versus retail acute pain sales, provide market analysis and forecast
by drug formulations, and forecast total acute pain drug sales for therapies
combination drugs are withdrawn from the U.S. market.